SCHEMBL7523650

SCHEMBL7523650

CC(=O)NC(C(=O)NCc1ccccc1)C(C)C

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.61
MEN1 O00255 2/20 0.61
CA12 O43570 1/20 0.61
CA1 P00915 1/20 0.61
CA2 P00918 1/20 0.61
CA3 P07451 1/20 0.61
CA4 P22748 1/20 0.61
CA6 P23280 1/20 0.61
CA5A P35218 1/20 0.61
CA7 P43166 1/20 0.61
CACNA1C Q13936 1/20 0.61
SCN9A Q15858 1/20 0.61
CA9 Q16790 1/20 0.61
CA13 Q8N1Q1 1/20 0.61
CA14 Q9ULX7 1/20 0.61
CA5B Q9Y2D0 1/20 0.61
ALDH1A1 P00352 3/20 0.58
MME P08473 1/20 0.55
SLC1A2 P43004 1/20 0.54
BACE1 P56817 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7523647 1.00 KMT2A (0.61) KMT2AMEN1CA12CA1CA2
SCHEMBL27417980 0.85 ALDH1A1 (0.49) KMT2AMEN1CA12CA1CA2
SCHEMBL27417981 0.85 ALDH1A1 (0.49) KMT2AMEN1CA12CA1CA2
SCHEMBL27998598 0.85 ALDH1A1 (0.56) KMT2AMEN1ALDH1A1SLC1A2BACE1
SCHEMBL12310879 0.84 KMT2A (0.58) KMT2AMEN1ALDH1A1MMESLC1A2
SCHEMBL14408875 0.84 KMT2A (0.58) KMT2AMEN1ALDH1A1MMESLC1A2
SCHEMBL993570 0.84 CA12 (0.64) KMT2AMEN1CA12CA1CA2
SCHEMBL6813286 0.84 CA12 (0.64) KMT2AMEN1CA12CA1CA2
SCHEMBL6814514 0.84 CA12 (0.64) KMT2AMEN1CA12CA1CA2
SCHEMBL24050019 0.84 BACE1 (0.59) KMT2AALDH1A1MMESLC1A2BACE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7598244-B2 [1,2,4]triazolo[1,5,a]pyrimidin-2-ylurea derivative and use thereof NIPPON KAYAKU KABUSHIKI KAISHA (JP) 2009-10-06 US disclosed
US-7598244-B2 [1,2,4]triazolo[1,5,a]pyrimidin-2-ylurea derivative and use thereof NIPPON KAYAKU KABUSHIKI KAISHA (JP) 2009-10-06 US disclosed
US-20070010515-A1 [1,2,4] Triazolo [1,5, a] pyrimidin-2-ylurea derivative and use thereof NIPPON KAYAKU KABUSHIKI KAISHA (JP) 2007-01-11 US disclosed
US-20070010515-A1 [1,2,4] Triazolo [1,5, a] pyrimidin-2-ylurea derivative and use thereof NIPPON KAYAKU KABUSHIKI KAISHA (JP) 2007-01-11 US disclosed
EP-0400440-B1 Amino acid derivative anticonvulsant RES CORP TECHNOLOGIES INC (US) 2002-03-13 EP disclosed
US-5654301-A Lacosamide FDA Orange book listed patent RESEARCH CORPORATION TECHNOLOGIES, INC. (US) 1997-08-05 US disclosed
US-5378729-A Diamide derivatives RESEARCH CORPORATION TECHNOLOGIES, INC. (US) 1995-01-03 US disclosed
WO-1992021648-A1 AMINO ACID DERIVATIVE ANTICONVULSANT RESEARCH CORPORATION TECHNOLOGIES, INC. (US) 1992-12-10 WO disclosed
EP-0194464-B1 AMINO ACID DERIVATIVES AND USE THEREOF FOR THE PREPARATION OF AN ANTICONVULSANT Research Corporation Technologies, Inc. (a Delaware corp.) (US) 1991-04-03 EP disclosed
WO-1990015069-A2 AMINO ACID DERIVATIVE ANTICONVULSANT RESEARCH CORPORATION TECHNOLOGIES, INC. (US) 1990-12-13 WO disclosed
EP-0400440-A1 Amino acid derivative anticonvulsant RESEARCH CORPORATION TECHNOLOGIES, INC. (US) 1990-12-05 EP disclosed
EP-0263506-A2 Anticonvulsant composition containing amino acid derivative and use of said amino acid derivative RESEARCH CORPORATION TECHNOLOGIES, INC. (US) 1988-04-13 EP disclosed
EP-0194464-A1 Amino acid derivatives and use thereof for the preparation of an anticonvulsant Research Corporation Technologies, Inc. (a Delaware corp.) (US) 1986-09-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070010515-A1 [1,2,4] Triazolo [1,5, a] pyrimidin-2-ylurea derivative and use thereof HLA-C, TPMT, TAP1 KMT2A 2048/4885MEN1 728/4885CA12 4076/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.